Contents

PREMED I: prevention of cystoid macular edema after cataract surgery in nondiabetics

April, 2018

Clinical Trial

European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1

Wielders LHP, Schouten JSAG, Winkens B, van den Biggelaar FJHM, Veldhuizen CA, Findl O, Murta JCN, Goslings WRO, Tassignon MJ, Joosse MV, Henry YP, Rulo AHF, Güell JL, Amon M, Kohnen T, Nuijts RMMA.

J Cataract Refract Surg. 2018 Apr;44(4):429-439.
Full text | Metrics.

Main finding: Patients treated with a combination of topical bromfenac and dexamethasone had a lower risk for developing cystoid macular oedema after cataract surgery than patients treated with a single drug.

 

  • Purpose: To compare the efficacy of a topical nonsteroidal antiinflammatory drug, topical corticosteroid, and a combination of both to prevent the occurrence of cystoid macular edema after cataract surgery in nondiabetic patients.
  • Study type: Randomized controlled Trial
  • Condition: Cataract surgery

Participants: ≥21 years requiring phacoemulsification cataract surgery, nondiabetics

 

  • n=914

 

Intervention:

 

Group 1: Topical bromfenac 0.09% bd 2 days pre-op until 2 weeks post-operatively
Group 2: Topical dexamethasone 0.1% QID 2 days pre-op and tapered over 4 weeks post-op
Group 3: Combination of topical bromfenac and dexamethasone

The incidence of clinically significant macular edema within 12 weeks postoperatively was 3.6%, 5.1%, and 1.5%, respectively.

Outcome Brom Dex Brom+Dex
Incidence of clinically significant macular oedema 3.6% 5.1% 1.5%

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2024 - sourceshed